and androgen deprivation therapy improved radiographic progression-free survival in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer, AstraZeneca announced. Roche said that ...

AstraZeneca (NASDAQ:AZN) reported positive results from a Phase 3 study of its drug Truqap in the treatment of PTEN-deficient de novo metastatic hormone-sensitive prostate cancer, or mHSPC.

We have used the SV-40 based TRAMP model of prostate cancer to explore the role of FGF2 and the PTEN tumor suppressor gene in prostate cancer progression. To accomplish this we crossed TRAMP mice to ...

UK-based pharmaceutical company AstraZeneca has reported positive results from its Phase III CAPItello-281 trial, which evaluated Truqap combined with abiraterone and androgen deprivation therapy ...

New research revealed tumor mutational burden was linked to improved event-free survival with pembrolizumab in early TNBC, ...

A physician survey finds a gap between guidelines and real-world clinical practice in treatment intensification for ...

Per AstraZeneca, the above results are the first to show that adding an ATK inhibitor to SoC can benefit mHSPC patients with tumor PTEN deficiency, an aggressive form of prostate cancer with a ...

including the IPATunity-170 trial in triple-negative breast cancer and IPATunity-130 in hormone receptor-positive, HER2-negative, and PTEN-mutated breast cancer. So far, no AKT inhibitors have ...

Mutations in PIK3CA, AKT1, and alterations in PTEN occur frequently, affecting up to 50% of patients with advanced HR-positive breast cancer, according to AZ. However, at the moment, testing for t ...

A machine learning tool incorporating both clinical and genomic data helps predict response to CDK4/6 inhibitor therapy in ...